These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3195000)

  • 1. Fosfestrol: Honvan, ST 52, Honvol, Fosfostilben. A review of new pharmacokinetic and clinical data. Workshop at the 3rd International Congress on Hormones and Cancer. Hamburg, September 6-11, 1987.
    Urol Int; 1988; 43 Suppl 1():1-58. PubMed ID: 3195000
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1988 Oct; 38(10):1502-12. PubMed ID: 3058134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer.
    Droz JP; Kattan J; Bonnay M; Chraibi Y; Bekradda M; Culine S
    Cancer; 1993 Feb; 71(3 Suppl):1123-30. PubMed ID: 8428334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasma levels of fosfestrol and its monophosphate, of diethylstilbestrol and its monoglucuronide following intravenous administration in patients with metastatic prostatic carcinoma].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1984; 34(10):1333-6. PubMed ID: 6542793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of fosfestrol and diethylstilbestrol in chronic hemodialysis patients with prostate cancer.
    Hatori M; Totuka Y; Yamanaka H
    Int J Urol; 2001 Dec; 8(12):681-5. PubMed ID: 11851768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasma concentrations of fosfestrol as well as diethylstilbestrol on their conjugates following intravenous administration on prostatic carcinoma patients].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1986 Aug; 36(8):1284-9. PubMed ID: 3778569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity and metabolism of E-DES-diphosphate.
    Oelschläger H; Rothley D; Dunzendorfer U
    Prog Clin Biol Res; 1989; 303():187-95. PubMed ID: 2780647
    [No Abstract]   [Full Text] [Related]  

  • 8. [Toxiderma induced by fosfestrol (ST52)].
    Fradet G; Deniaud C; Le Nechet A; Charlois T
    Ann Med Interne (Paris); 1997; 148(3):290-2. PubMed ID: 9255344
    [No Abstract]   [Full Text] [Related]  

  • 9. [Direct approximation of plasma concentration time curves of 3-diethylstilbestrol monoglucuronide following oral and intravenous administration of fosfestrol].
    Rothley D; Oelschläger H
    Pharmazie; 1986 Dec; 41(12):862-4. PubMed ID: 3575391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On the therapy of prostate carcinoma with honvan. Indication-application-contraindication].
    KLOSTERHALFEN H
    Z Urol; 1959 Jun; 52():354-9. PubMed ID: 14409971
    [No Abstract]   [Full Text] [Related]  

  • 11. [High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma].
    Kattan J; Droz JP; Culine S
    Bull Cancer; 1993 Mar; 80(3):248-54. PubMed ID: 8173177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diethylstilboestrol diphosphate, honvan (ST 52-asta), in intravenous tumour-specific chemotherapy of metastatic carcinoma of the prostate.
    HANSEN CC
    Acta Chir Scand; 1958 Apr; 114(5):398-413. PubMed ID: 13532319
    [No Abstract]   [Full Text] [Related]  

  • 13. [Honvan-high-dose therapy of prostatic carcinoma with metastases: early complications and value of prophylaxis against thrombosis].
    Heinz A; Meyer WW; Hallwachs O
    Urologe A; 1982 Jul; 21(4):232-4. PubMed ID: 6890263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assay of the synthetic estrogen fosfestrol in pharmaceutical formulations using capillary electrophoresis.
    G Themelis D; Trellopoulos AV; Tzanavaras PD; Karlberg B
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):559-63. PubMed ID: 15953702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of inoperable juvenile angiofibromas (author's transl)].
    Ganzer U; Meyer-Breiting E
    Laryngol Rhinol Otol (Stuttg); 1975 Nov; 54(11):871-4. PubMed ID: 172747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer.
    Siddiqui K; Abbas F; Biyabani SR; Ather MH; Talati J
    J Pak Med Assoc; 2004 Sep; 54(9):445-7. PubMed ID: 15518364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of prostate cancer treated with combined androgen-blockade].
    Kurita M; Kato Y; Tamura Y; Suzuki K; Yamanaka H
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):307-10. PubMed ID: 10700907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of intravenous fosfestrol tetrasodium (Honvan) infusion in treatment of symptomatic advanced prostate cancer.
    Williams AR; Whelan P
    Prostate Cancer Prostatic Dis; 1998 Jun; 1(4):204-207. PubMed ID: 12496896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case report of advanced breast cancer effectively treated by chemo-endocrine therapy with diethylstilbestrol diphosphate and cyclophosphamide].
    Hareyama M; Saito A; Oouchi A; Morita K
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2453-6. PubMed ID: 2751322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experiences in the therapy of prostate carcinoma with honvan].
    WARLITZ H
    Z Urol; 1959 Oct; 52():622-9. PubMed ID: 13842908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.